Pulmonx
This article was originally published in The Gray Sheet
Executive Summary
Series C financing round raises $8.3 mil. The privately-held, Palo Alto, California firm is preparing for clinical trials of its minimally invasive IntraBronchial Volume Reduction system for lung volume reduction treatment of chronic emphysema. The device is intended to eliminate the need for chest incision since it is introduced orally into the patient's airway. Tyco Ventures was the lead venture fund participating in the offering